Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries

Union Memorial Hospital and St. Agnes Hospital, Baltimore, Maryland, USA. Heartdrug@aol.com

OBJECTIVES: We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial. BACKGROUND: Platelet function may be impaired during thrombolysis in patients with an acute myocardial infarction. The effects of reteplase and alteplase on platelet aggregation and major surface antigen expression during the first 24 h of infarction therapy are unknown. METHODS: Platelet aggregation and receptor expression by flow cytometry were determined in 23 patients before thrombolysis and thereafter at 3, 6, 12 and 24 h. RESULTS: Aggregation was higher after reteplase at 24 h when induced by 5 micromol/liter adenosine diphosphate (ADP) (p = 0.007), 10 micromol/liter ADP (p = 0.02), collagen (p = 0.003) and thrombin (p = 0.009) than after alteplase. Reteplase therapy exhibited greater glycoprotein (GP) IIb/IIIa (p = 0.04), very late antigen-2 (p = 0.04) and platelet/endothelial cell adhesion molecule-I (p = 0.002) expression at 24 h. Trends toward decreased receptor expression early (3 to 6 h), followed by a progressive increase at 12 h and especially at 24 h occurred after both agents. CONCLUSIONS: In this prospective clinical ex vivo platelet study, similar patterns of platelet aggregation and surface receptor expression occurred during the first 24 h of coronary thrombolysis with reteplase and alteplase. However, after reteplase, indicators of platelet activity were higher at 24 h after thrombolysis than after alteplase. These data suggest that GP IIb/IIIa inhibitors or other antiplatelet strategies may be particularly advantageous when used 12 to 24 h after thrombolysis, especially after reteplase therapy. It is at this time point during the first day of coronary thrombolysis that GP IIb/IIIa is markedly expressed and platelets are most active.

This article has been cited by other articles:

				G. Ndrepepa, A. Schomig, and A. Kastrati The Only Better Alternative to Rescue Percutaneous Coronary Intervention Is Primary Percutaneous Coronary Intervention. J. Am. Coll. Cardiol., July 7, 2009; 54(2): 127 - 129. [Full Text] [PDF]

				A. Schomig, G. Ndrepepa, and A. Kastrati Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction Eur. Heart J., August 2, 2006; 27(16): 1900 - 1907. [Abstract] [Full Text] [PDF]

				V. L. Serebruany Comment: Mortality Benefit of No-Load Clopidogrel in COMMIT: Not a Surprise Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 99 - 101. [PDF]

				V. L. Serebruany, R. F. Suckow, T. B. Cooper, C. M. O'Connor, A. I. Malinin, K. R. R. Krishnan, L. T. van Zyl, V. Lekht, A. H. Glassman, and Sertraline Antidepressant Heart Attack Randomized Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression Am J Psychiatry, June 1, 2005; 162(6): 1165 - 1170. [Abstract] [Full Text] [PDF]

				A. Schomig, G. Ndrepepa, J. Mehilli, J. Dirschinger, S. G. Nekolla, C. Schmitt, S. Martinoff, M. Seyfarth, M. Schwaiger, A. Kastrati, et al. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2073 - 2079. [Abstract] [Full Text] [PDF]

				W. C. Lau, P. A. Gurbel, P. B. Watkins, C. J. Neer, A. S. Hopp, D. G.M. Carville, K. E. Guyer, A. R. Tait, and E. R. Bates Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance Circulation, January 20, 2004; 109(2): 166 - 171. [Abstract] [Full Text] [PDF]

				C. Gul, T. Kurum, M. Demir, G. Ozbay, O. Vural, O. Iqbal, and J. Fareed Acute Myocardial Infarction in a Patient with Essential Thrombocythemia Treated with Glycoprotein Ilb/Illa Inhibitor Clinical and Applied Thrombosis/Hemostasis, January 1, 2004; 10(1): 77 - 79. [Abstract] [PDF]

				P. A. Gurbel, K. P. Bliden, B. L. Hiatt, and C. M. O'Connor Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity Circulation, June 17, 2003; 107(23): 2908 - 2913. [Abstract] [Full Text] [PDF]

				M. Mirabet, D. Garcia-Dorado, J. Inserte, J. A. Barrabes, R.-M. Lidon, B. Soriano, M. Azevedo, F. Padilla, L. Agullo, M. Ruiz-Meana, et al. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1134 - H1141. [Abstract] [Full Text] [PDF]

				P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2 Circulation, June 19, 2001; 103(24): 2987 - 2992. [Full Text] [PDF]

				A.M. Antman, J.A. de Lemos, and E. Braunwald Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A8 - A13. [Abstract] [PDF]

				E. J. Topol, E. M. Ohman, P. W. Armstrong, R. Wilcox, A. M. Skene, P. Aylward, J. Simes, A. Dalby, A. Betriu, C. Bode, et al. Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction : Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial Circulation, October 10, 2000; 102(15): 1761 - 1765. [Abstract] [Full Text] [PDF]

				K. Peter, B. Kohler, A. Straub, J. Ruef, M. Moser, T. Nordt, M. Olschewski, M. E. Ohman, W. Kubler, and C. Bode Flow Cytometric Monitoring of Glycoprotein IIb/IIIa Blockade and Platelet Function in Patients With Acute Myocardial Infarction Receiving Reteplase, Abciximab, and Ticlopidine : Continuous Platelet Inhibition by the Combination of Abciximab and Ticlopidine Circulation, September 26, 2000; 102(13): 1490 - 1496. [Abstract] [Full Text] [PDF]

				S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14 Circulation, June 13, 2000; 101(23): 2690 - 2695. [Abstract] [Full Text] [PDF]

				F. van der Werf Should we transfer patients with acute myocarial infarcation to a tertiary care hospital for primary angioplasty? Eur. Heart J., May 2, 2000; 21(10): 792 - 793. [PDF]

				O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]

				E. J Topol CORONARY DISEASE: Acute myocardial infarction: thrombolysis Heart, January 1, 2000; 83(1): 122 - 122. [Full Text] [PDF]

				M. Moser, T. Nordt, K. Peter, J. Ruef, B. Kohler, M. Schmittner, R. Smalling, W. Kubler, and C. Bode Platelet Function During and After Thrombolytic Therapy for Acute Myocardial Infarction With Reteplase, Alteplase, or Streptokinase Circulation, November 2, 1999; 100(18): 1858 - 1864. [Abstract] [Full Text] [PDF]

				V. L. Serebruany, S. R. Murugesan, A. Pothula, D. Atar, D. R. Lowry, C. M. O'Connor, and P. A. Gurbel Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy Eur J Heart Fail, August 31, 1999; 1(3): 243 - 249. [Abstract] [Full Text] [PDF]

				R. T. F. Cheung, V. L. Serebruany, V. L. MD, and P. P. A. Gurbel Depressed Platelet Status in an Elderly Patient With Hemorrhagic Stroke After Thrombolysis for Acute Myocardial Infarction • Response Stroke, September 1, 1998; 29(9): 2002 - 2003. [Full Text]